Does the media refer more to QURE or ALLO?

In the previous week, Allogene Therapeutics had 1 more articles in the media than uniQure. MarketBeat recorded 4 mentions for Allogene Therapeutics and 3 mentions for uniQure. uniQure's average media sentiment score of 0.72 beat Allogene Therapeutics' score of 0.53 indicating that uniQure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment uniQure 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Allogene Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ALLO or IMNM more profitable?

Immunome's return on equity of -51.15% beat Allogene Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Allogene Therapeutics N/A -56.45% -40.36% Immunome N/A -51.15% -47.32%

Does the media prefer ALLO or IMNM?

In the previous week, Allogene Therapeutics had 3 more articles in the media than Immunome. MarketBeat recorded 4 mentions for Allogene Therapeutics and 1 mentions for Immunome. Immunome's average media sentiment score of 1.00 beat Allogene Therapeutics' score of 0.53 indicating that Immunome is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allogene Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunome 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, ALLO or KLRA?

Allogene Therapeutics is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Allogene Therapeutics N/A N/A -$190.89M -$0.77 N/A Kailera Therapeutics N/A N/A N/A -$3.65 thousand N/A

Is ALLO or KLRA more profitable?

Kailera Therapeutics' return on equity of 0.00% beat Allogene Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Allogene Therapeutics N/A -56.45% -40.36% Kailera Therapeutics N/A N/A N/A

Does the media prefer ALLO or KLRA?

In the previous week, Allogene Therapeutics had 1 more articles in the media than Kailera Therapeutics. MarketBeat recorded 4 mentions for Allogene Therapeutics and 3 mentions for Kailera Therapeutics. Allogene Therapeutics' average media sentiment score of 0.53 beat Kailera Therapeutics' score of 0.32 indicating that Allogene Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allogene Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kailera Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, KOD or ALLO?

Kodiak Sciences is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kodiak Sciences N/A N/A -$229.97M -$4.17 N/A Allogene Therapeutics N/A N/A -$190.89M -$0.77 N/A

Is KOD or ALLO more profitable?

Allogene Therapeutics' return on equity of -56.45% beat Kodiak Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Kodiak Sciences N/A -253.85% -81.48% Allogene Therapeutics N/A -56.45% -40.36%

Does the media favor KOD or ALLO?

In the previous week, Allogene Therapeutics had 2 more articles in the media than Kodiak Sciences. MarketBeat recorded 4 mentions for Allogene Therapeutics and 2 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 0.84 beat Allogene Therapeutics' score of 0.53 indicating that Kodiak Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kodiak Sciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Allogene Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, TRVI or ALLO?

Trevi Therapeutics is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Trevi Therapeutics N/A N/A -$42.76M -$0.32 N/A Allogene Therapeutics N/A N/A -$190.89M -$0.77 N/A

Is TRVI or ALLO more profitable?

Trevi Therapeutics' return on equity of -24.53% beat Allogene Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Trevi Therapeutics N/A -24.53% -23.37% Allogene Therapeutics N/A -56.45% -40.36%

Does the media refer more to TRVI or ALLO?

In the previous week, Trevi Therapeutics had 4 more articles in the media than Allogene Therapeutics. MarketBeat recorded 8 mentions for Trevi Therapeutics and 4 mentions for Allogene Therapeutics. Trevi Therapeutics' average media sentiment score of 0.75 beat Allogene Therapeutics' score of 0.53 indicating that Trevi Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trevi Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Allogene Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Allogene Therapeutics (ALLO) Competitors

$1.79 0.00 (0.00%)

Closing price 07/17/2026 04:00 PM Eastern

Extended Trading

$1.80 +0.01 (+0.34%)

As of 07/17/2026 07:22 PM Eastern

Compare

ALLO vs. QURE, IMNM, KLRA, KOD, and TRVI

Should you buy Allogene Therapeutics stock or one of its competitors? MarketBeat compares Allogene Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Allogene Therapeutics include uniQure (QURE), Immunome (IMNM), Kailera Therapeutics (KLRA), Kodiak Sciences (KOD), and Trevi Therapeutics (TRVI). These companies are all part of the "pharmaceutical products" industry.

How does Allogene Therapeutics compare to uniQure?

uniQure (NASDAQ:QURE) and Allogene Therapeutics (NASDAQ:ALLO) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

In the previous week, Allogene Therapeutics had 1 more articles in the media than uniQure. MarketBeat recorded 4 mentions for Allogene Therapeutics and 3 mentions for uniQure. uniQure's average media sentiment score of 0.72 beat Allogene Therapeutics' score of 0.53 indicating that uniQure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
uniQure	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Allogene Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

uniQure presently has a consensus target price of $64.17, indicating a potential upside of 59.42%. Allogene Therapeutics has a consensus target price of $8.52, indicating a potential upside of 376.10%. Given Allogene Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Allogene Therapeutics is more favorable than uniQure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
uniQure	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.65
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

78.8% of uniQure shares are owned by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are owned by institutional investors. 4.7% of uniQure shares are owned by insiders. Comparatively, 13.2% of Allogene Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

uniQure has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.46, meaning that its stock price is 54% less volatile than the broader market.

Allogene Therapeutics has a net margin of 0.00% compared to uniQure's net margin of -1,154.42%. Allogene Therapeutics' return on equity of -56.45% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
uniQure	-1,154.42%	-145.81%	-27.15%
Allogene Therapeutics	N/A	-56.45%	-40.36%

Allogene Therapeutics has lower revenue, but higher earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
uniQure	$16.10M	157.68	-$198.97M	-$3.48	N/A
Allogene Therapeutics	N/A	N/A	-$190.89M	-$0.77	N/A

Summary

Allogene Therapeutics beats uniQure on 11 of the 16 factors compared between the two stocks.

How does Allogene Therapeutics compare to Immunome?

Allogene Therapeutics (NASDAQ:ALLO) and Immunome (NASDAQ:IMNM) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, media sentiment, institutional ownership, profitability and dividends.

83.6% of Allogene Therapeutics shares are held by institutional investors. Comparatively, 44.6% of Immunome shares are held by institutional investors. 13.2% of Allogene Therapeutics shares are held by company insiders. Comparatively, 7.2% of Immunome shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Immunome's return on equity of -51.15% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics	N/A	-56.45%	-40.36%
Immunome	N/A	-51.15%	-47.32%

Allogene Therapeutics has higher earnings, but lower revenue than Immunome. Immunome is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics	N/A	N/A	-$190.89M	-$0.77	N/A
Immunome	$4.02M	629.57	-$212.39M	-$2.38	N/A

Allogene Therapeutics has a beta of 0.46, meaning that its stock price is 54% less volatile than the broader market. Comparatively, Immunome has a beta of 2.07, meaning that its stock price is 107% more volatile than the broader market.

In the previous week, Allogene Therapeutics had 3 more articles in the media than Immunome. MarketBeat recorded 4 mentions for Allogene Therapeutics and 1 mentions for Immunome. Immunome's average media sentiment score of 1.00 beat Allogene Therapeutics' score of 0.53 indicating that Immunome is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allogene Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunome	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Allogene Therapeutics presently has a consensus price target of $8.52, suggesting a potential upside of 376.10%. Immunome has a consensus price target of $33.17, suggesting a potential upside of 48.60%. Given Allogene Therapeutics' higher possible upside, equities analysts clearly believe Allogene Therapeutics is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
Immunome	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86

Summary

Allogene Therapeutics beats Immunome on 9 of the 15 factors compared between the two stocks.

How does Allogene Therapeutics compare to Kailera Therapeutics?

Allogene Therapeutics (NASDAQ:ALLO) and Kailera Therapeutics (NASDAQ:KLRA) are both pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends, profitability and media sentiment.

Allogene Therapeutics currently has a consensus target price of $8.52, suggesting a potential upside of 376.10%. Kailera Therapeutics has a consensus target price of $42.75, suggesting a potential upside of 130.46%. Given Allogene Therapeutics' higher probable upside, equities analysts plainly believe Allogene Therapeutics is more favorable than Kailera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
Kailera Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00

Allogene Therapeutics is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics	N/A	N/A	-$190.89M	-$0.77	N/A
Kailera Therapeutics	N/A	N/A	N/A	-$3.65 thousand	N/A

83.6% of Allogene Therapeutics shares are held by institutional investors. 13.2% of Allogene Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Kailera Therapeutics' return on equity of 0.00% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics	N/A	-56.45%	-40.36%
Kailera Therapeutics	N/A	N/A	N/A

In the previous week, Allogene Therapeutics had 1 more articles in the media than Kailera Therapeutics. MarketBeat recorded 4 mentions for Allogene Therapeutics and 3 mentions for Kailera Therapeutics. Allogene Therapeutics' average media sentiment score of 0.53 beat Kailera Therapeutics' score of 0.32 indicating that Allogene Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allogene Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kailera Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Allogene Therapeutics beats Kailera Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Allogene Therapeutics compare to Kodiak Sciences?

Kodiak Sciences (NASDAQ:KOD) and Allogene Therapeutics (NASDAQ:ALLO) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

Allogene Therapeutics' return on equity of -56.45% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kodiak Sciences	N/A	-253.85%	-81.48%
Allogene Therapeutics	N/A	-56.45%	-40.36%

Kodiak Sciences has a beta of 2.19, meaning that its share price is 119% more volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.46, meaning that its share price is 54% less volatile than the broader market.

In the previous week, Allogene Therapeutics had 2 more articles in the media than Kodiak Sciences. MarketBeat recorded 4 mentions for Allogene Therapeutics and 2 mentions for Kodiak Sciences. Kodiak Sciences' average media sentiment score of 0.84 beat Allogene Therapeutics' score of 0.53 indicating that Kodiak Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kodiak Sciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Allogene Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kodiak Sciences presently has a consensus target price of $42.14, indicating a potential downside of 1.17%. Allogene Therapeutics has a consensus target price of $8.52, indicating a potential upside of 376.10%. Given Allogene Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Allogene Therapeutics is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

Kodiak Sciences is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.17	N/A
Allogene Therapeutics	N/A	N/A	-$190.89M	-$0.77	N/A

89.1% of Kodiak Sciences shares are owned by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are owned by institutional investors. 44.4% of Kodiak Sciences shares are owned by company insiders. Comparatively, 13.2% of Allogene Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Allogene Therapeutics beats Kodiak Sciences on 10 of the 14 factors compared between the two stocks.

How does Allogene Therapeutics compare to Trevi Therapeutics?

Trevi Therapeutics (NASDAQ:TRVI) and Allogene Therapeutics (NASDAQ:ALLO) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.

Trevi Therapeutics currently has a consensus price target of $22.67, suggesting a potential upside of 18.86%. Allogene Therapeutics has a consensus price target of $8.52, suggesting a potential upside of 376.10%. Given Allogene Therapeutics' higher probable upside, analysts plainly believe Allogene Therapeutics is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

Trevi Therapeutics' return on equity of -24.53% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevi Therapeutics	N/A	-24.53%	-23.37%
Allogene Therapeutics	N/A	-56.45%	-40.36%

Trevi Therapeutics has a beta of 1, meaning that its stock price has a similar volatility profile to the broader market.Comparatively, Allogene Therapeutics has a beta of 0.46, meaning that its stock price is 54% less volatile than the broader market.

In the previous week, Trevi Therapeutics had 4 more articles in the media than Allogene Therapeutics. MarketBeat recorded 8 mentions for Trevi Therapeutics and 4 mentions for Allogene Therapeutics. Trevi Therapeutics' average media sentiment score of 0.75 beat Allogene Therapeutics' score of 0.53 indicating that Trevi Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trevi Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Allogene Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

95.8% of Trevi Therapeutics shares are held by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are held by institutional investors. 18.3% of Trevi Therapeutics shares are held by company insiders. Comparatively, 13.2% of Allogene Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Trevi Therapeutics is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.32	N/A
Allogene Therapeutics	N/A	N/A	-$190.89M	-$0.77	N/A

Summary

Trevi Therapeutics beats Allogene Therapeutics on 11 of the 13 factors compared between the two stocks.

Get Allogene Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALLO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALLO vs. The Competition

Export

Metric	Allogene Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$617.83M	$3.69B	$6.87B	$12.28B
Dividend Yield	N/A	2.17%	2.67%	9.34%
P/E Ratio	-2.32	21.03	27.25	23.92
Price / Sales	N/A	170.06	498.03	84.62
Price / Cash	N/A	154.08	52.99	60.41
Price / Book	1.38	8.26	10.69	6.18
Net Income	-$190.89M	$23.83M	$3.59B	$332.29M
7 Day Performance	-10.50%	-3.47%	-2.20%	-2.05%
1 Month Performance	-10.50%	2.69%	1.63%	-2.18%
1 Year Performance	43.20%	45.93%	25.64%	17.67%

Allogene Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALLO Allogene Therapeutics	1.9178 of 5 stars	$1.79 flat	$8.52 +376.1%	+43.2%	$617.83M	N/A	N/A	310	News Coverage Positive News
QURE uniQure	3.5715 of 5 stars	$41.10 -3.6%	$64.17 +56.1%	+168.5%	$2.69B	$16.10M	N/A	500
IMNM Immunome	3.4134 of 5 stars	$22.80 -2.4%	$33.17 +45.5%	+111.0%	$2.64B	$6.94M	N/A	40	Positive News Gap Down
KLRA Kailera Therapeutics	3.8557 of 5 stars	$19.97 -3.4%	$42.75 +114.1%	N/A	$2.59B	N/A	N/A	145	News Coverage Short Interest Increase
KOD Kodiak Sciences	0.8207 of 5 stars	$41.10 -0.5%	$42.14 +2.5%	+672.5%	$2.59B	N/A	N/A	90	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALLO) was last updated on 7/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Allogene Therapeutics (ALLO) Competitors

ALLO vs. QURE, IMNM, KLRA, KOD, and TRVI

How does Allogene Therapeutics compare to uniQure?

Summary

How does Allogene Therapeutics compare to Immunome?

Summary

How does Allogene Therapeutics compare to Kailera Therapeutics?

Summary

How does Allogene Therapeutics compare to Kodiak Sciences?

Summary

How does Allogene Therapeutics compare to Trevi Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALLO vs. The Competition

Allogene Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Allogene Therapeutics (ALLO) Competitors

ALLO vs. QURE, IMNM, KLRA, KOD, and TRVI

How does Allogene Therapeutics compare to uniQure?

Does the media refer more to QURE or ALLO?

Do analysts rate QURE or ALLO?

Do institutionals and insiders have more ownership in QURE or ALLO?

Which has more risk & volatility, QURE or ALLO?

Is QURE or ALLO more profitable?

Which has better valuation & earnings, QURE or ALLO?

Summary

How does Allogene Therapeutics compare to Immunome?

Do insiders & institutionals believe in ALLO or IMNM?

Is ALLO or IMNM more profitable?

Which has higher earnings & valuation, ALLO or IMNM?

Which has more risk and volatility, ALLO or IMNM?

Does the media prefer ALLO or IMNM?

Do analysts recommend ALLO or IMNM?

Summary

How does Allogene Therapeutics compare to Kailera Therapeutics?

Do analysts recommend ALLO or KLRA?

Which has preferable valuation & earnings, ALLO or KLRA?

Do insiders and institutionals believe in ALLO or KLRA?

Is ALLO or KLRA more profitable?

Does the media prefer ALLO or KLRA?

Summary

How does Allogene Therapeutics compare to Kodiak Sciences?

Is KOD or ALLO more profitable?

Which has more risk & volatility, KOD or ALLO?

Does the media favor KOD or ALLO?

Do analysts rate KOD or ALLO?

Which has higher earnings and valuation, KOD or ALLO?

Do institutionals and insiders believe in KOD or ALLO?

Summary

How does Allogene Therapeutics compare to Trevi Therapeutics?

Do analysts rate TRVI or ALLO?

Is TRVI or ALLO more profitable?

Which has more risk and volatility, TRVI or ALLO?

Does the media refer more to TRVI or ALLO?

Do institutionals & insiders hold more shares of TRVI or ALLO?

Which has preferable valuation & earnings, TRVI or ALLO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALLO vs. The Competition

Allogene Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools